MiNK Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for MiNK Therapeutics (INKT).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

3Buy

1Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$42Upside to Avg. PT+313.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$43→$50
May 18, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$35
Apr 1, 2026	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$35
Aug 15, 2025	HC Wainwright & Co.	Emily Bodnar	Upgrade	Neutral→Buy	$35
Jul 15, 2025	HC Wainwright & Co.	Emily Bodnar	Downgrade	Buy→Neutral	$35
Jul 14, 2025	William Blair	Matt Phipps	Downgrade	Outperform→Market Perform	—
Mar 18, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$35
Feb 25, 2025	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$9→$35
Nov 15, 2024	Baird	Jack Allen	PT Cut	Outperform	$80→$40
Nov 15, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
Oct 9, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
Aug 13, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
May 14, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
Mar 21, 2024	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$100→$90

Analyst Ratings News

PRO
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $35 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $35 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

HC Wainwright & Co. analyst Emily Bodnar upgrades MiNK Therapeutics (NASDAQ:INKT) from Neutral to Buy and maintains the price target from $35 to $35.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

HC Wainwright & Co. analyst Emily Bodnar downgrades MiNK Therapeutics (NASDAQ:INKT) from Buy to Neutral and maintains the price target from $35 to $35.

Benzinga Newsdesk

PRO
William Blair Downgrades MiNK Therapeutics to Market Perform

William Blair analyst Matt Phipps downgrades MiNK Therapeutics (NASDAQ:INKT) from Outperform to Market Perform.

Benzinga Newsdesk

MiNK Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

MiNK Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

PRO
William Blair Downgrades MiNK Therapeutics to Market Perform

People Also Watch

People Also Watch

MiNK Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

MiNK Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PROHC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PROHC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PROHC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PROHC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

PROWilliam Blair Downgrades MiNK Therapeutics to Market Perform

People Also Watch

People Also Watch

PRO
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

PRO
William Blair Downgrades MiNK Therapeutics to Market Perform